Raltegravir 600 mg film-coated tablets clinical trials

A randomized comparative phase II trial evaluating the capacity of the dual combination doravirine/raltegravir to maintain virological success in HIV-1 infected patients with an HIV-RNA plasma viremia below 50 copies/mL under a current antiretroviral regimen

This study looks at a new combination of medicines, doravirine and raltegravir, for people living with HIV. It checks if this combination can keep the virus levels very low for those already successfully managing their HIV with other treatments.